U.S. Markets closed

Bluebird Bio Stock Rises on Analyst’s Buy Call

Josh Nathan-Kazis

Bluebird Bio stock has fallen hard in recent months, despite the company receiving approval from European regulators for its gene therapy Zynteglo. Now is the time to buy, Maxim Group says.